Effect of ADP and Ionic Strength on the Kinetic and Motile Properties of Recombinant Mouse Myosin V*

Fei Wang‡, Lingfeng Chen‡, Oreste Arcucci‡, Estelle V. Harvey‡, Blair Bowers§, Yuhui Xu‡, John A. Hammer III§, and James R. Sellers‡

From the ‡Laboratory of Molecular Cardiology, §Laboratory of Cell Biology, and the ¶Core Microscopy Facility, NHLBI, National Institutes of Health, Bethesda, Maryland 20892

Mouse myosin V is a two-headed unconventional myosin with an extended neck that binds six calmodulins. Double-headed (heavy meromyosin-like) and single-headed (subfragment 1-like) fragments of mouse myosin V were expressed in Sf9 cells, and intact myosin V was purified from mouse brain. The actin-activated MgATPase of the tissue-purified myosin V, and its expressed fragments had a high Vmax and a low KATPase. Calcium regulated the MgATPase of intact myosin V but not of the fragments. Both the MgATPase activity and the in vitro motility were remarkably insensitive to ionic strength. Myosin V and its fragments translocated actin at very low myosin surface densities. ADP markedly inhibited the actin-activated MgATPase activity and the in vitro motility. ADP dissociated from myosin V subfragment 1 at a rate of about 11.5 s-1 under conditions where the Vmax was 3.3 s-1, indicating that, although not totally rate-limiting, ADP dissociation was close to the rate-limiting step. The high affinity for actin and the slow rate of ADP release helps the myosin head to remain attached to actin for a large fraction of each ATPase cycle and allows actin filaments to be moved by only a few myosin V molecules in vitro.

Fifteen classes of myosins have been defined based on sequence analysis of the conserved motor domain of the molecule (1, 2). There has been extensive biochemical characterization of myosins from class I and II (1). In addition, some of the in vitro properties of chicken brain myosin V have been reported (3, 4). Myosin V is a two-headed motor composed of two heavy chains weighing 212 kDa. Each heavy chain contains a typical myosin motor domain with a neck domain consisting of six IQ motifs that interact with myosin light chain subunits and calmodulin. Following this is a tail domain that contains regions of coiled-coil interspersed with nonhelical regions. Chicken myosin V copurifies with both calmodulin and essential light chain. The stoichiometry of the various light chains has not been rigorously determined (5). The elongated appearance of the myosin head in rotary shadowed electron micrographic images, however, is consistent with a neck region that has many light chain subunits (4). In addition, chicken brain myosin V contains another low molecular mass subunit (8 kDa) termed the "dynein light chain," which has also been found in association with several other proteins including dynein and nitric-oxide synthase (6).

Myosin V genes have been found in humans, rats, mice, chickens, Drosophila, Caenorhabditis elegans, and Saccharomyces cerevisiae (4, 7–13). There are two myosin V genes in yeast and at least two genes for myosin V in mammals, termed Va and Vb. Mutations in yeast and mouse myosin V genes reveal that this myosin likely functions in vesicle transport (see Ref. 2 for review). The dilute gene in mouse encodes myosin Va (9). dilute mutations are characterized by pale coat color, and the severe alleles also display neurological defects. The coat color phenotype is due to defective trafficking of the melanosome in melanocytes (14–17), whereas the neurological defects may be caused by alterations in synaptic transmission (18). Mutations in human myosin Va gene are responsible for Griscelli’s syndrome, which has similarities to the phenotypes exhibited by dilute mice (19).

Chicken myosin V has an actin-activated MgATPase activity that is markedly activated by calcium and has a high apparent affinity for actin as measured by the amount of actin required for half-maximal activation of the MgATPase activity (3, 4). Myosin V, when bound to a nitrocellulose-coated surface, moves actin filaments in the in vitro motility assay. A recent study provides strong evidence that a single myosin V molecule can act processively to translocate an actin filament (20). This type of motility requires that the myosin head remains attached to actin for a large fraction of each ATPase cycle (i.e. has a high duty ratio) and has a high affinity for actin.

We have expressed single-headed, subfragment 1 (S1)1-like and double-headed, heavy meromyosin-like (HMM) truncated fragments of mouse myosin V and have characterized the MgATPase activity and in vitro motility activity of these recombinant fragments. We found that the kinetic behavior of mouse myosin V is very different from that of conventional myosin II proteins and is altered so that cellular vesicles could be moved by just a few myosin V molecules. In addition, we have purified mouse brain myosin V and compared some of its biochemical properties to those of the recombinant fragments.

MATERIALS AND METHODS
Construction of Mouse Myosin V HMM-like Fragment into Baculovirus Transfer Vector—A full-length cDNA clone of mouse myosin Va was cut at a 5′ NotI prior to the ATG starting codon and a 3′ EcoRII site to give a fragment that encodes for 1091 amino acids corresponding to an HMM-like fragment. This fragment was subsequently linked to a FLAG epitope tag (DYKDDDDK or GACTACAAGGACGACGATGATAAG) followed by a stop codon and SmaI site at its 3′-end and

* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

† To whom correspondence should be addressed: Laboratory of Molecular Cardiology, NHLBI, NIH, 10 Center Dr., Bldg. 10, Rm. 8N202, Bethesda, MD 20892-1762. Tel.: 301-496-6887; Fax: 301-402-1542; E-mail: jsellers@helix.nih.gov.
subcloned into pVL1392 (Invitrogen), a baculovirus transfer vector, between the NotI and SmaI sites.

**Construction of Mouse Myosin V S1-like Fragment into Baculovirus Transfer Vector**—Using the above FLAG-tagged mouse V as a polymerase chain reaction template, a DNA fragment of about 900 base pairs containing the unique SfiI site at 1910 base pairs and 3'-ending at 2761 base pairs with the FLAG tag followed by a stop codon and SmaI site was generated. Substituting this polymerase chain reaction product into the above mouse myosin V HMM-like fragment in pVL1392 between sites SfiI and SmaI produced the desired mouse myosin V S1-like fragment of 907 amino acid residues for baculovirus expression.

**Preparation of Recombinant Proteins—**Baculoviruses were produced in a manner similar to that described by Pato et al. (21). Briefly, the baculovirus transfer vector containing the desired cDNA was transfected into Sf9 cells aided by BaccuGold DNA (PharMingen). The resulting baculovirus was plaque purified and amplified to a titer of 108 to 2 × 1010 plaque-forming units/ml, and stored at 4 °C as a stock for further use.

Sf9 cells (about 1 liter of culture) were coinfectected by the amplified heavy chain virus along with recombinant baculoviruses expressing calmodulin (a generous gift from Dr. Craig Montel, Johns Hopkins Medical School) and myosin essential light chain (LC17b) (22) for 3 days. After collection, the cell pellets were quickly frozen in liquid nitrogen and either used directly or stored at −80 °C. Thawed cell pellets were extracted with 10 mM MOPS (pH 7.0), 0.2 mM NaCl, 2 mM ATP, 10 mM MgCl2, 1 mM EGTA, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 5 mM luteinflupeptin, 1 mM diithiothreitol (DTT) and homogenized in a ground glass homogenizer. The mixture was stirred continuously in 4 °C for 20–30 min and sedimented at 47,000 × g for 10 min. The supernatant was mixed with Anti-FLAG M2 Affinity Gel (Sigma) and gently rocked for 1 h at 4 °C to ensure the binding of the FLAG-tagged myosin V to the affinity gel. This mixture was then sedimented at 1500 × g for 5 min. The gel pellet was washed once in buffer A (0.5 mM NaCl, 10 mM MOPS (pH 7.0), 0.1 mM EGTA, 1 mM DTT, 0.1 mM PMSF) and once with buffer A plus 1 mM ATP and 5 mM MgCl2 followed by another wash in buffer A alone. The gel was then washed with buffer B (10 mM MOPS (pH 7.0), 0.1 mM EGTA, 1 mM DTT, 0.1 mM PMSF) containing 1 mM EDTA followed by buffer A plus 1 mM EDTA to remove possible bound nucleotide. A final round of washes with buffer B followed by buffer A was carried out. The low ionic strength washes helps to remove a FLAG antibody cross-reactive protein of about 110 kDa. The gel was then resuspended in buffer A and packed into a column and washed further with buffer A. The FLAG-tagged myosin V HMM or S1 was eluted with buffer A containing 0.5 mg/ml FLAG peptide. The eluted fragments were analyzed by electrophoresis on a 15% SDS-polyacrylamide gel electrophoresis gel. The fractions containing myosin V HMM were pooled and concentrated by precipitation with 60% (NH4)2SO4, followed by sedimentation at 47,000 × g for 10 min. The pellet was solubilized in 1–5 ml of buffer B (200 mM KCl, 10 mM MOPS (pH 7.0), 0.1 mM EGTA, 1 mM DTT, 0.1 mM PMSF) and dialyzed in 1 liter of the same buffer overnight with two changes to remove residual ammonium sulfate and ATP. The protein concentration was determined according to the method of Cooper et al. (26).

**Measurement of the Rate of in Vitro Motility—**The rates of motility of actin filaments sliding over the expressed myosin fragments were measured as described previously in a buffer consisting of 80 mM KCl, 20 mM MOPS (pH 7.4), 5 mM MgCl2, 1 mM ATP, 0.1 mM EGTA, 50 mM DTT, 2.5 mg/ml glucose, 2 μg/ml catalase, 0.1 mg/ml glucose oxidase at 30 °C (25) unless otherwise specified. The myosin was applied to the flow chamber at concentrations ranging from 0.2 mg/ml to 40 ng/ml. Both uncoated glass and nitrocellulose-coated coverslips were used. The rhodamine phalloidin-labeled (Molecular Probes) actin filaments were imaged with a microchannel plate intensified CCD (ICCD-350F, VideoScope) and recorded on sVHS videotape (Panasonic). The rate of actin filament sliding was quantified using the Cell Trak system (Motion Analysis) as described previously (25).

**Stopped Flow Experiments—**ADP release experiments were carried out using SF-2001 Stopped Flow apparatus (KinTek Corp.) in a buffer containing 100 mM KC1, 10 mM MOPS (pH 7.0), 2 mM MgCl2, 0.1 mM EGTA, 1 μM calmodulin at 20 °C. Pyrene-labeled actin was prepared according to the method of Cooper et al. (26). One syringe contained 0.2 μM pyrene actomyosin V S1 mixed with various concentrations of ADP, and the other contained 400 μM ATP.

**Activation of ATP—**It was necessary to purify ATP used in the stopped flow experiments to remove residual ADP contamination. A 10-ml solution of 15 mM ATP (Sigma) in 10 mM triethylamine (pH 7.5) was applied to a 1 × 20-cm column of Q-Sepharose Fast Flow (Amersham Pharmacia Biotech) equilibrated in 10 mM triethylamine (pH 7.5) at 4 °C. The column was developed with a linear gradient (total volume, 400 ml) from 10 to 600 mM triethylamine (pH 7.5). The absorbance at 260 nm was monitored. Fractions were pooled from the peak and descending limb of the curve and rotary evaporated (keeping the temperature less than 15 °C) to dryness. Three washes and evaporations with methanol were carried out at 4 °C to remove residual triethylamine. The ATP powder containing less than 0.05% ADP was dissolved in 10 mM HEPES, pH 7.5 and stored at −80 °C until used.

**Electron Microscopy—**Samples at approximately 0.1 mg protein/ml were diluted with two parts of glycerol and sprayed on freshly cleaved mica, as described by Uber and Branton (27). The samples were rotary shadowed in a Balzers 301 freeze-fracture unit at an angle of 7° for the platinum. The shadowing was carried out a room temperature.

**RESULTS**

**Purification of the Expressed Myosin V Fragments—**Two 3’-truncations of the cDNA encoding the heavy chain of mouse myosin Va were produced (Fig. 1). The first was truncated after codon 1091 to produce an HMM-like molecule containing the motor domain, six IQ motifs, and 184 amino acids of the coiled-coil to form a dimer. The second construct was truncated after codon 907 to produce a monomeric S1-like molecule containing the motor domain and all six IQ motifs that comprise the neck region. In addition, each construct was tagged at its 3’-end with the FLAG epitope to facilitate purification. The heavy chain constructs were cloned into pVL1392 vectors for baculovirus expression and were coinfectected into Sf9 cells along with viruses that encode calmodulin and essential light chain. Both proteins were purified from Sf9 cell extracts using affinity chromatography over a FLAG antibody column. The purified proteins are shown in Fig. 2.

The myosin V HMM preparation was rotary shadowed and examined by electron microscopy. The sample showed a mixture of double-headed and single-headed fragments (Fig. 3A).
The single-headed fragments still contained a rod, which suggests that there was proteolysis at the head-neck junction of only one of the two heavy chains leaving the coiled coiled region intact. Bands corresponding to the proteolytically produced rods can be seen in Fig. 2 migrating between the 21- and 31-kDa markers. These bands, in addition to the heavy chain band seen at 116 kDa, reacted with the FLAG antibody, indicating that they contained the FLAG epitope at the carboxyl terminus. It is likely that the proteolysis was occurring within the Sf9 cells, because the proteolytic products could be detected in Sf9 cells that were directly lysed into boiling SDS (data not shown). The amount of cleavage was not affected by homogenization in an mixture containing numerous protease inhibitors and did not appear to increase with time. The site of proteolysis is predicted to be within the IQ regions based on the molecular mass of the fragments. The proportion of double-headed HMM varied from preparation to preparation and ranged from 50 to 80%. Not all preparations were checked by electron microscopy, but the amount of degradation on SDS gels was monitored. In contrast, the myosin V S1 preparation appeared homogeneous by rotary shadowing (Fig. 3B). Because of this complication, we have chosen to concentrate primarily on the characterization of myosin V S1 in this study but will present some supporting data from the HMM preparation.

A strong band corresponding to calmodulin could be seen with Coomassie Blue staining of 15% SDS-polyacrylamide gels (Fig. 2), and the presence of a very small amount of essential light chain could be detected by Western blotting with an essential light chain antibody in some but not all preparations. Quantitative Western blotting was used to estimate the stoichiometry of essential light chain bound. Western blots were performed on equal amounts of purified recombinant myosin V S1 and purified recombinant nonmuscle myosin IIA HMM using the assumption that the myosin IIA HMM heavy chain binds 1 mol of essential light chain/mol. Comparison of the intensities of the detected bands revealed that myosin V S1 bound much less than 0.1 mol of essential light chain/mol of heavy chain, and, thus, most of the IQ motifs are occupied by calmodulin. In most preparations no essential light chains were detected. Western blots of the cell extract indicated that sufficient essential light chain was being produced (data not shown). Therefore, the substoichiometric binding of essential light chain was not a consequence of limiting levels of essential light chain in the Sf9 cells. This is in contrast to chicken brain myosin V, which copurifies with 1–2 mol of essential light chain/mol.

To reconcile the difference between our recombinant mouse proteins and the tissue-purified chicken brain preparation, we purified myosin V from mouse brain. This preparation showed bands corresponding to the heavy chain, calmodulin, and the dynein light chain, but no essential light chain (Fig. 4, lane 2). Western blotting of the preparation with an essential light chain antibody also failed to detect any essential light chain in the preparation (Fig. 4, lane 4), although it detected the essential light chain of a rod in the single-headed HMMs, but no essential light chain in the preparation (Fig. 4, lane 2). There is a small amount of a contaminating protein at 55 kDa that probably corresponds to tubulin (23).

MgATPase Activity of Myosin V HMM and S1—Both myosin V HMM and S1 exhibited a low MgATPase activity in the absence of actin of less than 0.04 s⁻¹. Actin markedly activated the MgATPase activity of both fragments (Table I) in a temperature- and ionic strength-dependent manner. At 37 °C the V_max values of HMM and S1 were greater than 10 s⁻¹. The...
Characterization of Mouse Myosin V Fragments

**FIG. 4.** Mouse brain myosin V does not contain essential light chain. Lanes 1 and 2, 4–20% SDS-polyacrylamide gel; lanes 3 and 4, Western blot with anti-essential light chain antibody. Lanes 1 and 3, human platelet actomyosin; lanes 2 and 4, tissue-purified mouse brain myosin V. HC, heavy chain; LC20, regulatory light chain 20 kDa; CaM, calmodulin; DLC, dynein light chain.

**FIG. 5.** Calmodulin dependence of the actin-activated MgATPase activity of myosin V S1. The MgATPase activity of myosin V S1 was measured in the presence of various concentrations of calmodulin. The symbols represent the data from two independent experiments. The conditions of the assay was 20 μM actin, 80 mM KCl, 10 mM MOPS (pH 7.0), 2 mM MgCl₂, 0.1 mM EGTA, 1 mM ATP, 37 °C.

**TABLE I**

| Expressed myosin V | Temperature (°C) | [KCl] (mM) | Calmodulin | V<sub>max</sub> (s<sup>-1</sup>) | K<sub>ATPase</sub> (μM) |
|--------------------|-----------------|-----------|------------|-----------------|-----------------|
| HMM                | 25              | 80        | ND         | 3.8 ± 0.6       | 0.15 ± 0.06     |
|                    | 35              | 80        | ND         | 11.2 ± 1.1      | 1.4 ± 0.5       |
|                    | 25              | 250       | ND         | 1.6 ± 0.3       | 1.7 ± 0.1       |
|                    | 35              | 250       | ND         | 1.9 ± 0.1       | 4.0 ± 1.0       |
| S1                 | 37              | 80        | –          | 4.0 ± 2.3       | 2.5 ± 0.4       |
|                    | 25              | 80        | +          | 4.5 ± 0.4       | 4.4 ± 1.0       |
|                    | 37              | 80        | +          | 12.0 ± 3.5      | 4.0 ± 1.0       |
|                    | 25              | 250       | +          | 2.0 ± 0.3       | 24.0 ± 4.3      |
|                    | 37              | 250       | +          | 6.6 ± 1.1       | 30.0 ± 4.5      |

* ND, no effect was detected.

K<sub>ATPase</sub> was remarkably low with a value of 0.15 μM being recorded for the HMM preparation at 25 °C with 80 mM KCl added (total ionic strength, 92 mM). Addition of exogenous calmodulin did not affect the actin-activated MgATPase activity of HMM but did increase that of some preparations of S1. The dependence of this increase in actin-activated MgATPase on calmodulin concentration was measured, and a half-maximal value of about 1 μM was determined (Fig. 5). This probably represents calmodulin binding to one or more of the IQ domains.

Calcium did not activate the MgATPase activity of either myosin V HMM or S1. However, the tissue-purified mouse brain myosin V behaved very differently. In the absence of calcium, its MgATPase activity was 0.1 s<sup>-1</sup> at 4 μM actin, 80 mM KCl, 37 °C even in the presence of exogenously added calmodulin. The activity was stimulated to 2.2 s<sup>-1</sup> by the addition of calcium. In the presence of both calcium and exogenous calmodulin, the V<sub>max</sub> of the tissue-purified mouse brain myosin V was 11 s<sup>-1</sup>, and the K<sub>ATPase</sub> was 0.8 μM, similar to values obtained for the recombinant HMM under the same ionic conditions.

Another interesting feature of MgATPase activities is the ionic strength dependence. The K<sub>ATPase</sub> values for the expressed S1, HMM, and the tissue-purified mouse brain myosin V are remarkably low at 80 mM KCl, and that of HMM is still very low even at 250 mM KCl (Table 1).

**In Vitro Motility of Myosin V HMM and S1**—Myosin V HMM and S1 both supported movement of actin filaments when bound either to a nitrocellulose-coated surface or directly to glass coverslips. The rate of movement was faster for HMM than for S1 under comparable ionic conditions. At 40 mM KCl the rate for HMM was 0.35 ± 0.05 μm/s compared with 0.20 ± 0.03 μm/s for S1. In agreement with previous reports with intact chicken brain myosin V (3), we found that the mouse myosin V fragments could support actin filament sliding even at very low concentrations of myosin V added to the coverslip surface. If flow cells were coated with myosin V fragment concentrations from 20 to 200 μg/ml, actin filaments were rapidly sheared into small fragments. At applied concentrations of 1–2 μg/ml or less, however, actin filaments moved over the surface in a constant manner without shearing. As the surface density decreased, actin filaments translocated through apparently fixed points of attachment to the surface that allowed for Brownian driven rotation of the moving actin filaments. Myosin V HMM supported actin filament sliding at applied concentrations of 40 ng/ml in the presence of methylcellulose, a viscous reagent which suppresses lateral Brownian diffusion. No movement of actin filaments was seen over such sparsely coated surfaces in the absence of methylcellulose. The myosin V S1 is roughly comparable with the myosin V HMM in its ability to support actin filament sliding at low concentrations. The mouse brain myosin V translocated actin filaments somewhat faster than did either the HMM or S1 fragment. The rate of actin translocation was 0.46 μm/s (average of two preparations) for the tissue-purified mouse brain myosin V as compared with 0.27 μm/s for myosin V HMM under comparable conditions (20 mM KCl in the standard motility assay buffer).

The translocation of actin filaments by myosin V fragments was not affected by the presence of tropomyosin. The movement became slower and more erratic as a function of time in calcium containing buffers probably as a result of calmodulin dissociation from the neck of myosin V.

In addition, we have examined the ionic strength dependence of in vitro motility. S1 can support the movement of actin filaments even at 400 mM KCl in the absence of methylcellulose (Fig. 6). HMM behaved similarly (data not shown). Thus, the motile properties of myosin V fragments differs dramatically from those of conventional myosin II molecules both in dependence of motility on the myosin concentration and in the ionic strength dependence.

**Effect of ADP on In Vitro Motility and MgATPase Activity**—The rate of actin filament sliding by myosin V S1 was examined as a function of ADP concentration at a constant ATP concentration of 200 μM (Fig. 7). As a comparison, the same experiment was conducted with rabbit skeletal muscle HMM. ADP...
inhibited the rate of actin filament sliding of the myosin V S1 much more potently than it did that of rabbit skeletal muscle HMM. The rate of actin filament sliding was reduced to 50% of its maximal value at an ADP concentration of about 25 mM for myosin V. By contrast, greater than 200 mM ADP was needed to inhibit the rate of actin filament sliding by skeletal muscle HMM only by a comparable amount. Myosin V HMM behaved similarly to myosin V S1 in this assay.

ADP also inhibited the actin-activated MgATPase activity of myosin V S1 (Fig. 8). Over the range of ADP concentrations studied, no clear plateau in activity was determined, but it is clear that the ATPase activity was inhibited over a similar range of ADP concentrations as was used to inhibit the in vitro motility.

Rate of ADP Release from Actomyosin V S1 and Affinity of Actomyosin V S1 for ADP—Stopped flow spectrofluorimetry was used to measure the rate of ADP release from an actomyosin S1 complex. When pyrene-labeled actin binds to myosin, the fluorescent signal is quenched by 80% (28). The complex of actin and myosin V S1 dissociated at a rate of 46 s⁻¹ when rapidly mixed with 200 mM ATP (Fig. 9A). At ADP concentrations between 0.05 and 5 μM, the ATP-induced dissociation of ternary complexes of actin, myosin V S1, and ADP occurred as a bi-exponential process (Fig. 9A). The fast phase had a rate constant similar to that for the dissociation of acto-S1 by ATP and corresponded to dissociation of the acto-S1 complex that had no ADP bound. The amplitude of the slow phase increased with increasing ADP concentrations and occurred at a rate of 11.5 ± 0.8 s⁻¹. The percentage of slow phase amplitude was plotted versus the ADP concentration (Fig. 9B). The data were fitted by a hyperbola that yielded a Kd of 0.77 mM for the binding of ADP to pyrene-actomyosin V S1. It was necessary to use ATP that has been column purified for this experiment because commercial sources of ATP contained 0.7–1.3% ADP as measured by a linked assay using pyruvate kinase, phosphoenolpyruvate, NADH, and lactate dehydrogenase. The kinetic experiments were performed at 20 °C to facilitate com-
parison with numerous published studies of other myosins. The $V_{\text{max}}$ and $K_{\text{ATPase}}$ of the steady state $\text{MgATPase}$ activity under these conditions were 3.3 $\text{s}^{-1}$ and 4.3 $\text{mM}$, respectively. Thus, the rate constant for release of ADP is quite close to the steady state rate, and ADP release may be partially rate-limiting.

**DISCUSSION**

Studies of single-headed and double-headed myosin fragments have been essential to elucidation of myosin function. Here, we report the characterization of such fragments from an unconventional myosin, mouse myosin Va. There are several advantages for using recombinant expression of myosin fragments versus tissue purification of the myosin. We can purify up to 7 mg of myosin fragment from a 1-liter culture of Sf9 cells using FLAG affinity chromatography, whereas tissue purification of chicken brain myosin V yields less than 1 mg/100 g of brain (23). Furthermore, the ability to study the kinetics of a single-headed fragment greatly simplifies the initial kinetic characterizations, particularly of a myosin that might move processively on an actin filament, and thus involves coordinated action of the two heads.

Chicken brain myosin V has previously been purified and shown to contain calmodulin and essential light chain as subunits in addition to a lower molecular mass subunit that is identical to a previously reported dynein light chain (3, 5). The expressed recombinant mouse myosin V fragments did not bind essential light chain, even though it was coexpressed along with calmodulin and heavy chain in the Sf9 cells. We, therefore, purified mouse brain myosin V to examine its subunit composition. It contains myosin heavy chain, calmodulin, and dynein light chain but no essential light chain. Thus, the composition of the neck regions of myosin V from these two species must be different.

Myosin V has three unique kinetic features compared with myosin II. First, its apparent affinity for actin in the presence of ATP is much higher than that of most myosin II subfragments. Second, its actin-activated $\text{MgATPase}$ activity is much less sensitive to increasing ionic strength than that of rabbit skeletal muscle subfragments. The $K_{\text{ATPase}}$ of the V HMM is 1 $\text{mM}$ or less at 80 $\text{mM}$ KCl concentration (ionic strength, 92 $\text{mM}$) and is still remarkably low even at the unphysiologically high KCl concentration of 250 $\text{mM}$ (ionic strength, 262 $\text{mM}$). The high affinity of myosin V for actin is related to its ability to translocate actin at low myosin surface densities in vitro, another feature that distinguishes myosin V from myosin II class mol-

**FIG. 9.** ADP inhibition of ATP-induced dissociation of pyrene-acto-S1 complex. A, observed fluorescence changes upon mixing of 200 $\mu$M ATP with 0.1 $\mu$M pyrene-acto-S1 and 0, 0.5, and 2.5 $\mu$M ADP. The curve in the absence of ATP was fit to a single exponential with a rate of 45.8 $\text{s}^{-1}$. The curves in the presence of ADP were fit to the sum of two exponentials. For the experiment in which 0.5 $\mu$M ADP was used, the amplitudes and rates were $-0.451$ $\text{mV}$, 56 $\text{s}^{-1}$, and $-0.351$ $\text{mV}$, 11.6 $\text{s}^{-1}$. For the experiment in which 2.5 $\mu$M ADP was used, the amplitudes and rates were $-0.162$ $\text{mV}$, 56.4 $\text{s}^{-1}$ and $-0.082$ $\text{mV}$, 10.8 $\text{s}^{-1}$, respectively. The experiment was determine at ADP concentrations ranging from 0.05 to 5 $\mu$M. B, [ADP] dependence of the slow phase amplitude percentage. The best fit to a hyperbola gave a $K_d$ values of 0.77 $\mu$M. Control experiments (not shown) demonstrated that ADP did not cause dissociation of the pyrene-acto-S1 complex. The conditions of the reaction are given under “Experimental Procedures.” Note that the ATP and ADP concentrations mentioned here are the concentrations after mixing.
ecules. Third, myosin V has a very high affinity of ADP.

The $V_{\text{max}}$ of the actin-activated MgATPase activity of mouse myosin V HMM and S1 is quite high (10–12 s$^{-1}$) and was not activated by calcium. In fact, calcium exerted a slight inhibitory effect in the absence of calmodulin. In contrast, the actin-activated MgATPase activity of tissue-purified mouse brain myosin V is very low in the absence of calcium (0.1 s$^{-1}$ at 4 $\mu$M actin, 80 mM KCl, 37 °C) but is activated to a $V_{\text{max}}$ of 11 s$^{-1}$ with a $K_{\text{ATPase}}$ of 0.8 $\mu$M under conditions that were the same except for the addition of calcium and exogenous calmodulin. Calmodulin by itself is not sufficient to stimulate the activity. The requirement for calcium is similar to that of chicken brain myosin V. Interestingly, neither tissue-purified myosin V preparations require calcium for $in\ vitro$ motility (4). Nascimento et al. (4) digested chicken brain myosin V with calpain that cleaves at two sites. One site is in the tail, which produces an ADP slow release of ADP compared with the steady state MgATPase rate. Together, this type of kinetics assure that the myosin has a high duty cycle ratio, i.e. is attached for a significant fraction of its kinetic cycle. Thus, a two-headed myosin V molecule might be able to remain bound to actin via one head while the other head is detached and repriming for its next power stroke. Even if myosin V does not have the same ability to undergo long range processive movements as has been demonstrated with fluorescently labeled kinesin molecules on microtubules (35), its kinetics are such that only a few myosin V molecules at the interface between a vesicle and an actin filament should be sufficient to drive transport.

Acknowledgments—We thank Drs. Robert S. Adelstein and Earl Homsher for comments on the manuscript and Drs. Justin Molloy and Claudia Veigel for helpful discussions. We especially thank Dr. Kang Rao for performing numerous Western blots and for help with mouse brain dissection.

REFERENCES

1. Sellers, J. R. (1999) Myosins, Oxford University Press, Oxford

2. Mermall, V., Post, P. L., and Mooseker, M. S. (1998) Science 279, 527–533

3. Coyne, R. E., O’Shea, M. E., Heuser, J. E., Cuello, M. V., Wolenski, J. S., Espureffo, E. M., Forscher, P., Larson, R. E., and Mooseker, M. S. (1995) Cell 75, 13–23

4. Nascimento, A. A. C., Cheney, R. E., Tsuchiya, S. B. F., Larson, R. E., and Mooseker, M. S. (1996) J. Biol. Chem. 271, 17561–17569

5. Espindola, F. S., Cheney, R. E., King, S. M., Suter, D. M., and Mooseker, M. S. (1996) Mol. Biol. Cell 7, 372 (abstr.)

6. Benashski, S. E., Harrison, A., Patel-King, R. S., and King, S. M. (1997) J. Biol. Chem. 272, 20929–20935

7. Engle, L. J., and Kennett, R. H. (1994) Genomics 10, 407–416

8. Zhao, L. P., Kusolovsky, J. S., Reinhardt, J., Bahler, M., Witt, A. E., Provance, D. W., Jr., and Mercer, J. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 10826–10831

9. Mercer, J. A., Seperack, P. K., Strobel, M. C., Copeland, N. G., and Jenkins, N. A. (1991) Nature 349, 709–713

10. Bonaff, N., and Sellers, J. R. (1998) J. Muscle Res. Cell Motil. 19, 129–141

11. Baker, J. P., and Titus, M. A. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 539–552

12. Haarer, B. K., Petzold, A., Lilie, S. H., and Brown, S. S. (1994) J. Cell Sci. 107, 1055–1064

13. Wu, X., Bowers, B., Rao, K., Wei, Q., and Hammer, J. A., III (1998) J. Cell Biol. 143, 1–20

14. Wu, X., Bowers, B., Wei, Q., Kocher, B., and Hammer, J. A., III (1997) J. Cell Sci. 110, 847–859

15. Provance, D. W., Jr., Wei, M., Ipe, V., and Mercer, J. A. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 14555–14558

16. Wei, Q., Wu, X. F., and Hammer, J. A., III (1997) J. Muscle Res. Cell Motility 18, 517–527

17. Prekeris, R., and Terrian, D. M. (1997) J. Biol. Chem. 272, 1598–1601

18. Pastural, E., Barrat, F. J., Dufourcq-Lagelouse, R., Certain, S., Sanal, O., Jabado, N., Seger, R., Griscelli, C., Fischer, A., and De Saint Basile, G. (1997) Nat. Genet. 16, 235–240

19. Mehta, A. D., Rock, H. S., Ridif, M., Spudich, J. A., Mooseker, M. S., and Cheney, R. E. (1999) Nature 460, 590–593

20. Pato, M. D., Sellers, J. R., Preston, Y. A., Harvey, E. V., and Adelstein, R. S. (1990) J. Biol. Chem. 271, 2689–2695

21. Lash, J. A., Helper, D. J., Klug, M., Nicolaoukas, A. W., and Hathaway, D. B. (1990) Nucleic Acids Res. 18, 7176–7176

22. Cheney, R. E. (1999) Methods Enzymol. 298, 3–18

23. Pollard, T. D., and Korn, E. D. (1978) J. Biol. Chem. 248, 4682–4690

24. Homsher, E., Wang, F., and Sellers, J. R. (1992) Am. J. Physiol. Cell Physiol. 262, C714–C723

25. Cooper, J. A., Walker, S. B., and Pollard, T. D. (1983) J. Muscle Res. Cell Motil. 4, 253–262

26. Uber, A., and Branton, D. (1980) J. Cell Biol. 71, 95–102

27. Kurzawa, S. E., and Gjeve, M. A. (1996) J. Muscle Res. Cell Motil. 17, 669–676

28. Siemankowski, R. F., Wiseman, M. O., and White, H. D. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 658–662

29. Coluccio, L. M., and Gjeve, M. A. (1999) J. Biol. Chem. 274, 21575–21580

30. Cremo, C. R., and Geeves, M. A. (1998) Biochemistry 37, 1969–1978

31. Ritchie, M. D., Gjeve, M. A., Woodward, S. K. A., and Mannstein, D. J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 8619–8623

32. Coluccio, L. M., and Geeves, M. A. (1996) Mol. Biol. Cell 7, 226a

33. Hancock, W. O., and Howard, J. (1998) J. Cell Biol. 140, 1395–1405

34. Vale, R. D., Funatsu, T., Pierce, D. W., Romberg, L., Harada, Y., and Yanagida, T. (1996) Nature 380, 451–453